Name | Number of supported studies | Average coverage | |
---|---|---|---|
plasma cell | 6 studies | 29% ± 9% | |
epithelial cell | 5 studies | 29% ± 12% | |
ciliated cell | 3 studies | 24% ± 5% |
Insufficient scRNA-seq data for expression of HSD17B8 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
thymus | 100% | 1437.92 | 653 / 653 | 100% | 97.56 | 605 / 605 |
liver | 100% | 1345.69 | 226 / 226 | 100% | 89.82 | 404 / 406 |
prostate | 100% | 677.48 | 245 / 245 | 99% | 48.85 | 498 / 502 |
kidney | 100% | 1334.47 | 89 / 89 | 98% | 53.67 | 885 / 901 |
pancreas | 100% | 1689.09 | 328 / 328 | 98% | 41.11 | 174 / 178 |
adrenal gland | 100% | 1203.10 | 258 / 258 | 96% | 41.65 | 221 / 230 |
intestine | 99% | 647.83 | 952 / 966 | 97% | 45.19 | 511 / 527 |
lung | 98% | 512.33 | 568 / 578 | 97% | 45.74 | 1115 / 1155 |
stomach | 99% | 586.02 | 354 / 359 | 95% | 34.40 | 271 / 286 |
brain | 94% | 326.76 | 2492 / 2642 | 99% | 34.17 | 696 / 705 |
breast | 99% | 636.87 | 456 / 459 | 94% | 44.88 | 1047 / 1118 |
esophagus | 97% | 628.71 | 1408 / 1445 | 95% | 28.10 | 174 / 183 |
ovary | 89% | 339.50 | 160 / 180 | 99% | 46.69 | 426 / 430 |
uterus | 92% | 321.25 | 156 / 170 | 96% | 50.39 | 441 / 459 |
bladder | 90% | 459.05 | 19 / 21 | 94% | 43.86 | 476 / 504 |
skin | 88% | 873.20 | 1598 / 1809 | 95% | 42.04 | 450 / 472 |
eye | 0% | 0 | 0 / 0 | 100% | 71.10 | 80 / 80 |
tonsil | 0% | 0 | 0 / 0 | 100% | 52.03 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 50.02 | 1 / 1 |
spleen | 100% | 713.84 | 240 / 241 | 0% | 0 | 0 / 0 |
muscle | 99% | 542.51 | 791 / 803 | 0% | 0 | 0 / 0 |
adipose | 97% | 415.01 | 1171 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 97% | 57.73 | 28 / 29 |
heart | 95% | 535.18 | 815 / 861 | 0% | 0 | 0 / 0 |
blood vessel | 82% | 214.85 | 1096 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 62% | 320.51 | 575 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006703 | Biological process | estrogen biosynthetic process |
GO_0006633 | Biological process | fatty acid biosynthetic process |
GO_0008209 | Biological process | androgen metabolic process |
GO_0051290 | Biological process | protein heterotetramerization |
GO_0005740 | Cellular component | mitochondrial envelope |
GO_1990204 | Cellular component | oxidoreductase complex |
GO_0005886 | Cellular component | plasma membrane |
GO_0005759 | Cellular component | mitochondrial matrix |
GO_0004303 | Molecular function | estradiol 17-beta-dehydrogenase [NAD(P)+] activity |
GO_0106386 | Molecular function | (3R)-hydroxyacyl-CoA dehydrogenase (NAD+) activity |
GO_0047035 | Molecular function | testosterone dehydrogenase (NAD+) activity |
GO_0005515 | Molecular function | protein binding |
GO_0070404 | Molecular function | NADH binding |
Gene name | HSD17B8 |
Protein name | (3R)-3-hydroxyacyl-CoA dehydrogenase (EC 1.1.1.n12) (17-beta-hydroxysteroid dehydrogenase 8) (17-beta-HSD 8) (HSD17B8) (3-ketoacyl-[acyl-carrier-protein] reductase alpha subunit) (KAR alpha subunit) (3-oxoacyl-[acyl-carrier-protein] reductase) (Estradiol 17-beta-dehydrogenase 8) (EC 1.1.1.62) (Protein Ke6) (Ke6) (Short chain dehydrogenase/reductase family 30C member 1) (Testosterone 17-beta-dehydrogenase 8) (EC 1.1.1.239) |
Synonyms | SDR30C1 HKE6 FABGL RING2 |
Description | FUNCTION: Required for the solubility and assembly of the heterotetramer 3-ketoacyl-[acyl carrier protein] (ACP) reductase functional complex (KAR or KAR1) that forms part of the mitochondrial fatty acid synthase (mtFAS). Alpha-subunit of the KAR complex that acts as a scaffold protein required for the stability of carbonyl reductase type-4 (CBR4, beta-subunit of the KAR complex) and for its 3-ketoacyl-ACP reductase activity, thereby participating in mitochondrial fatty acid biosynthesis. Catalyzes the NAD-dependent conversion of (3R)-3-hydroxyacyl-CoA into 3-ketoacyl-CoA (3-oxoacyl-CoA) with no chain length preference; this enzymatic activity is not needed for the KAR function . Prefers (3R)-3-hydroxyacyl-CoA over (3S)-3-hydroxyacyl-CoA and displays enzymatic activity only in the presence of NAD(+) . Cooperates with enoyl-CoA hydratase 1 in mitochondria, together they constitute an alternative route to the auxiliary enzyme pathways for the breakdown of Z-PUFA (cis polyunsaturated fatty acid) enoyl-esters (Probable) . NAD-dependent 17-beta-hydroxysteroid dehydrogenase with highest activity towards estradiol (17beta-estradiol or E2). Has very low activity towards testosterone and dihydrotestosterone (17beta-hydroxy-5alpha-androstan-3-one). Primarily an oxidative enzyme, it can switch to a reductive mode determined in the appropriate physiologic milieu and catalyze the reduction of estrone (E1) to form biologically active 17beta-estradiol . . |
Accessions | Q92506 ENST00000427295.2 ENST00000230236.4 ENST00000454191.2 ENST00000374662.4 ENST00000414463.2 ENST00000422433.2 |